OS Benefit from TTFields with Gemcitabine/Nab-paclitaxel for Patients with Unresectable Locally Advanced Pancreatic Adenocarcinoma By Ogkologos - August 4, 2025 755 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PANOVA-3 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Worried Cancer Patients Face Delayed Treatment Because Of Pandemic April 1, 2020 Osimertinib After Definitive Chemoradiotherapy Prolongs PFS in Patients with Unresectable Stage... June 6, 2024 Data from a Large Cohort of Patients with mRCC Demonstrate the... September 21, 2020 Implementation of Door-to-Door HPV-based Cervix Screening Results in Better Attendance of... April 17, 2023 Load more HOT NEWS Is there a right way to check your body for cancer? From smart knives to virtual reality tumours: five innovations in understanding... Countdown to 100,000 OncoLife Survivorship Care Plans: How it all started Cancer in My Community: Addressing Health Disparities in Brazil
